Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

Could Actiphage provide rapid TB test in sub-Saharan Africa?

Sub-Saharan Africa is devastated by TB disease. Zambia, has a high TB/HIV burden – 59,000 people developed TB in 2020 and 15,000 died. There is a critical need for a non-sputum based rapid test for diagnosing TB disease.
  • March 23, 2022
  • Human health, International, Latest, Press release
  • human TB, TB diagnostic
rapid TB test World TB Day - Zambart image

To address the unmet need for a rapid TB test, PBD Biotech is collaborating with the London School of Hygiene and Tropical Medicine UK, Zambart in Zambia and the University of Leicester UK, on a project in Lusaka, Zambia to test the sensitivity of its Actiphage blood test for Mycobacterium tuberculosis, the cause of TB.

Sub-Saharan Africa is devastated by TB disease. The project will focus on Zambia, which has a high TB/HIV burden – 59,000 people developed TB in 2020, of which 23,000 also had HIV, and 15,000 died of the disease. The country has a population of just 19.4m so the disease has considerable social and economic impact.

Actiphage can rapidly detect the presence of the Mycobacterium tuberculosis in a blood sample, removing the need for the patient to produce sputum. This offers the potential to screen a high-risk population to identify people with the disease and potentially control the disease through treatment.

The research is being led by Dr Lily Telisinghe, of the London School of Hygiene and Tropical Medicine, with Dr Pranab Haldar, Clinical Senior Lecturer at University of Leicester, who led the first study showing promising outcomes using Actiphage as a blood-based TB diagnostic in a UK TB cohort, and Dr Ben Swift, Director of Research and Development at PBD Biotech.

Lily Telisinghe says: “The early human data using Actiphage in the UK are promising but need to be cautiously interpreted. Zambia is a high TB/HIV prevalence setting, with health system infrastructure and challenges that are representative of those across much of sub-Saharan Africa. We are excited to collaborate on this project, which will provide data on the feasibility of using Actiphage in the field and its sensitivity for diagnosing TB disease.”

Pranab Haldar agrees that it is an important project. “The study will provide us with valuable experience using the Actiphage test and knowledge of how it may add value in a high TB burden setting.”

Ben Swift comments: “The pandemic has highlighted the vital role of rapid detection in containing and managing infection. In pilot trials, Actiphage has been shown to be effective in detecting TB at an early stage and we are delighted to be starting a larger study in Zambia.

“Morbidity and mortality from TB are significantly increased in individuals with HIV. The incidence of both these conditions in Zambia means that an accurate diagnosis could make a massive, immediate, benefit to the lives of thousands.”

The one-year study started in 2022.

Find out more at:

https://www.stoptb.org/static_pages/ZMB_Dashboard.html

https://www.who.int/news-room/fact-sheets/detail/tuberculosis

Share:

Related posts

Loading...
AACC webinar phage-based TB diagnostics

PBD Biotech announces AACC webinar to support awareness of new TB diagnostics

March 23, 2023
We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic tests that are urgently needed to screen LTBI and determine who will progress to active TB disease.
AACC webinar phage-based TB diagnostics

PBD Biotech announces AACC webinar to support awareness of new TB diagnostics

March 23, 2023
We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic...
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis...
Marie Roskrow

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

January 17, 2023
Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need, PBD Biotech is announcing that it has appointed Dr Marie Roskrow to chair its board and has expanded its scientific...
Marie Roskrow

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

January 17, 2023
Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need,...
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic...
1 2 Next »

developers of phage-based diagnostics

Contact Us
BIVDA member 2023

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!